Stockscreener 앱 받기
0.311
2.54%
0.0077
시간 외 거래:
.31
-0.001
-0.32%
IGC Pharma Inc 주식(IGC)의 최신 뉴스
Market Recap: IGC Pharma Inc (IGC)’s Positive Momentum, Closing at 0.32 - The Dwinnex
Page 3 | IGC PHARMA INC Trade Ideas — TRADEGATE:IGS1 - TradingView
IGC Pharma, Inc. (IGC) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease - Joplin Globe
Revolutionary Voice AI Could Detect Alzheimer's Before Symptoms ShowIGC's Breakthrough - StockTitan
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline - ACCESS Newswire
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy - ACCESS Newswire
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies - ACCESS Newswire
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge - ACCESS Newswire
IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor - Markets Insider
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 - AccessWire
Geode Capital Management LLC Has $240,000 Stock Holdings in IGC Pharma, Inc. (NYSEMKT:IGC) - Defense World
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets - Big News Network
IGC Pharma to Unveil Alzheimer's Pipeline and AI Drug Discovery Updates at Investor Chat - StockTitan
Amazon To Sell Ad Tools To Third Parties - Baystreet.ca
IGC Gains on Word of Alzheimer’s Treatment - Baystreet.ca
IGC Pharma's CALMA Trial Triples Alzheimer's Patient Recruitment with AI-Powered Strategy - StockTitan
IGC Pharma to Present at BIO Partnering @ JPM 2025 Healthcare Conference - StockTitan
What Makes IGC Pharma, Inc. (IGC) a New Buy Stock - MSN
Ascendiant Capital Markets Forecasts Strong Price Appreciation for IGC Pharma (NYSEMKT:IGC) Stock - Defense World
IGC Pharma expands clinical research program for IGC-AD1 - Nasdaq
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology - AccessWire
IGC Pharma's Alzheimer's Drug Shows 50% Memory Improvement in Early Studies - StockTitan
IGC.WS (India Globalization Capital) EV-to-FCF : 0.00 (As of Nov. 30, 2024) - GuruFocus.com
Otsuka Corp (OSUKF) QuotePress Release - The Globe and Mail
Cannabinoid Drug For Agitation In Alzheimer's Yields Cognitive Improvements In Clinical Trial - Inkl
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment - BioSpace
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of He - GuruFocus.com
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasin - GuruFocus.com
IGC (IGC Pharma) Price-to-Operating-Cash-Flow : (As of Nov. 14, 2024) - GuruFocus.com
IGC Pharma Reports 42% Revenue Growth, Advances Multiple Alzheimer's Drug Candidates - StockTitan
IGC Pharma CEO Reveals AI-Driven Strategy in Alzheimer's and Weight Loss Drug Development | IGC Stock News - StockTitan
IGC Pharma (STU:IGS1) Asset Turnover : 0.03 (As of Jun. 2024) - GuruFocus.com
MD’s IGC Pharma enrolls patients in Phase 2 trial for Alzheimer’s dementia drug - Maryland Daily Record
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1 - AccessWire
1.03%
자본화:
|
볼륨(24시간):